SPY411.45-1.41 -0.34%
DIA337.53+0.74 0.22%
IXIC13,857.84-138.26 -0.99%

BRIEF-Relmada Therapeutics Released Conclusions Of The Preclinical Abuse Studies On Rel-1017 (Esmethadone) Recently Completed

· 03/15/2021 17:48
BRIEF-Relmada Therapeutics Released Conclusions Of The Preclinical Abuse Studies On Rel-1017 (Esmethadone) Recently Completed

- Relmada Therapeutics Inc RLMD.O:

  • RELMADA THERAPEUTICS INC - RELEASED THE CONCLUSIONS OF THE PRECLINICAL ABUSE STUDIES ON REL-1017 (ESMETHADONE) RECENTLY COMPLETED

  • RELMADA - ABSTRACT TO BE PRESENTED INCLUDES REL-1017 DID NOT PRODUCE INITIAL OR CUMULATIVE NEUROTOXIC EFFECTS OR OTHER EVIDENCE OF DAMAGE TO CORTICAL NEURONS

Source: (https://bit.ly/2NrNU5G)

Further company coverage: RLMD.O


((Reuters.Briefs@thomsonreuters.com;))